+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Autoimmune Disease Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904622
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Autoimmune Disease Drugs Market grew from USD 116.79 billion in 2024 to USD 125.86 billion in 2025. It is expected to continue growing at a CAGR of 7.55%, reaching USD 180.81 billion by 2030.

Mapping the Evolution of Autoimmune Therapeutics

The global landscape of autoimmune disease therapeutics has experienced an extraordinary evolution over the past decade. Advances in molecular biology, immunology, and biomanufacturing have converged to propel the development of novel therapies that modulate immune responses with unprecedented precision. From the early introduction of monoclonal antibodies to the rapid expansion of small molecule inhibitors, the field has matured into a dynamic marketplace characterized by intense innovation and rigorous competition.

As the prevalence of autoimmune conditions continues to climb, driven by aging populations and heightened awareness of early detection, stakeholders across the value chain face both opportunities and challenges. Payers are demanding robust evidence of real-world effectiveness and cost efficiency, regulatory bodies are refining pathways for accelerated approval, and patient advocacy groups are amplifying the need for personalized, safe, and convenient treatment options. In this context, research and development investments are being channeled toward biologic modalities, next-generation inhibitors, and novel delivery systems.

Against this backdrop, this executive summary distills key market drivers, regulatory shifts, and competitive dynamics that define the current and future state of autoimmune therapeutics. By synthesizing segmentation analyses, regional performance metrics, and corporate strategies, this report equips decision-makers with the insights needed to prioritize initiatives, allocate resources, and capitalize on emerging trends in an increasingly complex environment.

Pioneering Innovations Reshaping Autoimmune Treatment Paradigms

The autoimmune drug sector is undergoing a transformative era marked by groundbreaking scientific breakthroughs and shifting stakeholder expectations. Precision immunomodulation has emerged as a central theme, with therapies targeting specific cytokines, cell subsets, and intracellular signaling pathways. This movement toward tailored interventions is redefining clinical practice and fostering a shift away from broad-spectrum immunosuppression.

Concurrently, the rise of biosimilars is reshaping the cost landscape. As originator biologics face patent expirations, biosimilar entrants are driving price competition and expanding patient access. Meanwhile, innovations in formulation and delivery have led to subcutaneous and self-administered options that reduce treatment burden and enhance adherence outside hospital settings. These shifts are catalyzing new treatment paradigms and challenging traditional distribution models.

Digital health initiatives and real-world evidence platforms are also gaining traction. Remote monitoring solutions, patient-reported outcome tools, and predictive analytics are enabling more dynamic management of chronic autoimmune conditions. In an interconnected ecosystem, data sharing between providers, payers, and pharmaceutical partners is facilitating outcome-based contracting and value-driven care models. Together, these trends signal a departure from one-size-fits-all approaches toward a more integrated, patient-centric paradigm.

Assessing the Ramifications of 2025 US Tariff Adjustments

The implementation of adjusted United States tariff structures in 2025 introduces new complexities for stakeholders in the autoimmune therapeutics market. By recalibrating import duties on active pharmaceutical ingredients and finished biologics, these policy changes are influencing cost bases, supply chain strategies, and pricing decisions. Manufacturers that rely heavily on international production of key drug components are assessing the financial impact of elevated levies and exploring diversification of sourcing to mitigate exposure.

In response, some companies are accelerating efforts to localize manufacturing capabilities, investing in domestic bioprocessing facilities and contract development partnerships within North America. At the same time, cost pressures are prompting collaboration with toll manufacturers that offer integrated services at competitive rates. Payers and healthcare providers are closely monitoring the potential downstream effects on treatment affordability, with contract negotiations increasingly factoring in tariff-induced cost variability.

Despite these headwinds, there is optimism that strategic adaptation will preserve momentum in drug development. Stakeholders anticipate that incremental price adjustments can be balanced by efficiency gains in production, streamlined regulatory pathways for domestically produced therapies, and enhanced supply chain resilience. Ultimately, the capacity to navigate tariff adjustments effectively will distinguish those organizations that maintain market leadership from those that face margin erosion under new trade conditions.

Nuanced Perspectives Across Drug Class, Mechanism, Administration, Indication, Distribution, and End User

A comprehensive understanding of the autoimmune drug market emerges through multiple analytical lenses that capture the complexity of product, mechanism, delivery, clinical application, distribution, and end-user dynamics. When framed by drug class distinctions, leading-edge biologics command a significant share of therapeutic innovation, encompassing fusion proteins designed to intercept immune signaling, monoclonal antibodies that target specific antigens, and peptide constructs engineered for enhanced stability and receptor engagement. Alongside these, biosimilars are gaining traction as cost-effective alternatives, and small molecules continue to drive oral convenience and intracellular pathway modulation.

Evaluating the mechanisms of action provides further granularity. Agents designed to deplete B cells are proving transformative in conditions characterized by autoantibody production, while inhibitors of interleukin subfamilies-ranging from IL-17’s role in barrier immunity to IL-23’s involvement in T helper cell expansion and IL-6’s contribution to systemic inflammation-are unlocking new therapeutic avenues. JAK inhibitors, stratified by JAK1 selectivity or dual JAK1/2 targeting and extending to JAK3 suppression, offer oral modulation of cytokine signaling, complementing the established blockade of tumor necrosis factor pathways.

The route of administration shapes patient and provider preferences. Oral options, available as capsules, solutions, or tablets, emphasize convenience and adherence. Parenteral modalities, delivered intravenously or via subcutaneous injection, enable precise dosing and immediate bioavailability. Topical formulations, in creams or ointments, address localized cutaneous manifestations with minimized systemic exposure.

Indication-based segmentation reveals distinct growth pockets. Inflammatory bowel disease encompasses both Crohn’s disease and ulcerative colitis, each presenting unique immunopathological challenges. Systemic conditions such as lupus, multiple sclerosis, and rheumatoid arthritis continue to drive demand for long-acting systemic therapies. Dermatological indications like plaque psoriasis and psoriatic arthritis benefit from targeted cytokine inhibitors, reflecting the convergence of dermatology and rheumatology.

Distribution channels span hospital pharmacies that serve acute and specialty settings, online platforms that include dedicated pharmacy webstores and third-party marketplaces, and retail outlets divided between chain networks and independent community dispensaries. Ultimately, the end users of these therapies-whether in clinics managed by general practitioners or specialists, homecare environments with nurse-assisted or self-administered regimens, or hospitals operating within secondary and tertiary care infrastructures-define the final mile of delivery and patient experience.

Geographic Trends Driving Global Autoimmune Drug Dynamics

Regional performance in the autoimmune therapeutics market reflects a tapestry of demographic trends, regulatory frameworks, and healthcare infrastructure maturity. In the Americas, robust funding for research, a high prevalence of autoimmune conditions, and established reimbursement pathways underpin sustained growth. Market access strategies increasingly emphasize value demonstration through real-world evidence, especially in the United States where payer scrutiny is most pronounced. Canada and Latin American markets are expanding at a measured pace, with government initiatives to bolster local manufacturing and streamline approval processes.

The Europe, Middle East & Africa region presents diverse market dynamics shaped by jurisdictional complexity. In Western Europe, national health services and centralized procurement drive pricing negotiations and tendering processes. Central and Eastern Europe are experiencing a convergence toward EU regulatory standards, fostering greater consistency in market entry requirements. Within the Middle East, investments in healthcare modernization and the establishment of specialized immunology centers are catalyzing demand, while in Africa, partnerships between public health agencies and private entities aim to improve access and build pharmacovigilance capabilities.

In Asia-Pacific, rapid economic growth, increasing healthcare spending, and expanding private insurance coverage are propelling market expansion. Countries such as China, Japan, and South Korea are at the forefront of domestic innovation, with government incentives encouraging biomanufacturing and clinical trial activity. Emerging markets like India and Southeast Asian nations are witnessing rising adoption of biosimilars as a cost management strategy, alongside growing infrastructure for cold chain logistics and specialty pharmacy services. Collectively, these regional forces are shaping a global ecosystem in which cross-border collaboration and adaptive commercialization models become critical for success.

Competitive Landscape Highlights Leading Autoimmune Drug Developers

The competitive landscape of autoimmune therapeutics is dominated by a cadre of established pharmaceutical leaders and nimble biotech innovators. Several global organizations have cemented their positions through a combination of pioneering R&D, strategic acquisitions, and diversified portfolios. Renowned for their extensive immunology pipelines, some of these players maintain leadership in monoclonal antibody development, with flagship products generating multibillion-dollar revenues while fresh molecules advance through late-stage clinical trials.

Parallel to these incumbents, specialized biotech firms are carving out niches by focusing on next-generation mechanisms of action and novel delivery modalities. Their agility enables rapid iteration of clinical strategies and the pursuit of biomarker-driven studies, often in partnership with academic institutions or contract research organizations. Moreover, manufacturers of biosimilars are intensifying competition by establishing regional production hubs, securing interchangeability designations, and negotiating favorable tender agreements.

Recent corporate activities underscore the dynamic nature of this segment. High-profile licensing deals are facilitating the co-development of innovative candidates, while vertical integration strategies are streamlining the journey from molecule discovery to commercial supply. Amid escalating competition, organizations are placing greater emphasis on lifecycle management, deploying formulation enhancements, and extending exclusivity through patent strategies. As the market expands, the ability to sustain a robust innovation pipeline, optimize manufacturing footprints, and execute effective market access initiatives will determine leadership in autoimmune disease therapeutics.

Strategic Imperatives for Decision Makers in Autoimmune Drug Sector

To navigate the complexities of autoimmune drug development and commercialization, organizations should adopt a multipronged strategic approach. First, investing in precision medicine capabilities-including genomic profiling, biomarker identification, and digital health platforms-will differentiate product offerings and support outcome-based contracting. Embedding real-world evidence generation into clinical development programs can accelerate payer acceptance and demonstrate long-term value to healthcare systems.

Second, establishing resilient supply chains through geographic diversification of manufacturing and strategic partnerships can mitigate the impact of trade policy shifts and raw material shortages. Embracing advanced manufacturing technologies, such as continuous bioprocessing and modular facility designs, can enhance flexibility and cost efficiency.

Third, fostering collaborations with contract research and manufacturing organizations allows for scalable resource allocation and accelerates time to market. These alliances should extend beyond transactional engagements to include joint innovation initiatives and data-sharing arrangements.

Fourth, tailoring market access strategies to regional reimbursement landscapes is essential. Early engagement with health technology assessment bodies, proactive evidence generation for local health economics, and targeted patient support programs will optimize product uptake. Finally, building a robust portfolio management framework that balances established therapies with next-generation candidates ensures sustainable growth. By aligning R&D priorities with emerging clinical needs and regulatory evolutions, industry leaders can secure a competitive edge in a rapidly evolving environment.

Rigorous Analytical Framework Underpinning Research Insights

This research draws upon a rigorous analytical framework that integrates primary and secondary data sources to ensure comprehensive and accurate insights. Primary inputs include in-depth interviews with key stakeholders such as industry executives, regulatory authorities, payers, clinicians, and patient advocacy representatives. These discussions inform the interpretation of market dynamics, unmet needs, and strategic priorities across geographic regions.

Secondary research encompasses a thorough review of peer-reviewed literature, regulatory filings, clinical trial registries, corporate investor presentations, and proprietary industry databases. Data triangulation methods are employed to reconcile disparate figures and validate trends, while SWOT analyses provide a structured evaluation of competitive positioning.

Quantitative modeling leverages historical performance data and segment-specific metrics to chart market shares, revenue distribution, and pipeline progression without extrapolating future estimates. Qualitative assessments contextualize these findings within broader healthcare system evolutions, policy shifts, and technological advancements.

An iterative validation process, involving cross-functional expert panels, ensures that conclusions are grounded in practical experience and evolving industry best practices. Throughout, adherence to ethical standards and data integrity principles underpins the credibility of our research outcomes.

Synthesizing Insights for the Future of Autoimmune Therapeutics

As the autoimmune therapeutics landscape continues to mature, the confluence of scientific innovation, regulatory evolution, and market dynamics will create both challenges and opportunities for industry participants. Stakeholders that harness precision medicine, foster supply chain resilience, and execute targeted market access strategies are poised to lead the next wave of therapeutic breakthroughs.

Emerging modalities, from advanced biologics to orally administered small molecule inhibitors, will redefine treatment paradigms and patient experiences. Regional disparities in healthcare infrastructure and policy will necessitate adaptive commercialization models that respect local needs while leveraging global best practices.

The path forward demands agility, collaboration, and a steadfast commitment to demonstrating clinical and economic value. By integrating robust evidence generation with forward-thinking portfolio management, organizations can navigate policy headwinds, drive sustainable growth, and ultimately improve outcomes for patients living with autoimmune diseases.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Biologics
      • Fusion Proteins
      • Monoclonal Antibodies
      • Peptides
    • Biosimilars
    • Small Molecules
  • Mechanism Of Action
    • B Cell Depleting Agents
    • Il Inhibitors
      • Il17 Inhibitors
      • Il23 Inhibitors
      • Il6 Inhibitors
    • Jak Inhibitors
      • Jak1 Inhibitors
      • Jak1/2 Inhibitors
      • Jak3 Inhibitors
    • Tnf Inhibitors
  • Route Of Administration
    • Oral
      • Capsule
      • Solution
      • Tablet
    • Parenteral
      • Intravenous
      • Subcutaneous
    • Topical
      • Cream
      • Ointment
  • Indication
    • Inflammatory Bowel Disease
      • Crohn's Disease
      • Ulcerative Colitis
    • Lupus
    • Multiple Sclerosis
    • Psoriasis
      • Plaque Psoriasis
      • Psoriatic Arthritis
    • Rheumatoid Arthritis
  • Distribution Channel
    • Hospital Pharmacies
    • Online Channels
      • Pharmacy Webstores
      • Third Party Marketplaces
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • End User
    • Clinics
      • General Practice
      • Specialist Clinics
    • Homecare Settings
      • Nurse Assisted
      • Self Administered
    • Hospitals
      • Secondary Care
      • Tertiary Care
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • Eli Lilly and Company
  • Amgen Inc.
  • Merck & Co., Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Autoimmune Disease Drugs Market, by Drug Class
8.1. Introduction
8.2. Biologics
8.2.1. Fusion Proteins
8.2.2. Monoclonal Antibodies
8.2.3. Peptides
8.3. Biosimilars
8.4. Small Molecules
9. Autoimmune Disease Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. B Cell Depleting Agents
9.3. Il Inhibitors
9.3.1. Il17 Inhibitors
9.3.2. Il23 Inhibitors
9.3.3. Il6 Inhibitors
9.4. Jak Inhibitors
9.4.1. Jak1 Inhibitors
9.4.2. Jak1/2 Inhibitors
9.4.3. Jak3 Inhibitors
9.5. Tnf Inhibitors
10. Autoimmune Disease Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.2.1. Capsule
10.2.2. Solution
10.2.3. Tablet
10.3. Parenteral
10.3.1. Intravenous
10.3.2. Subcutaneous
10.4. Topical
10.4.1. Cream
10.4.2. Ointment
11. Autoimmune Disease Drugs Market, by Indication
11.1. Introduction
11.2. Inflammatory Bowel Disease
11.2.1. Crohn's Disease
11.2.2. Ulcerative Colitis
11.3. Lupus
11.4. Multiple Sclerosis
11.5. Psoriasis
11.5.1. Plaque Psoriasis
11.5.2. Psoriatic Arthritis
11.6. Rheumatoid Arthritis
12. Autoimmune Disease Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Channels
12.3.1. Pharmacy Webstores
12.3.2. Third Party Marketplaces
12.4. Retail Pharmacies
12.4.1. Chain Pharmacies
12.4.2. Independent Pharmacies
13. Autoimmune Disease Drugs Market, by End User
13.1. Introduction
13.2. Clinics
13.2.1. General Practice
13.2.2. Specialist Clinics
13.3. Homecare Settings
13.3.1. Nurse Assisted
13.3.2. Self Administered
13.4. Hospitals
13.4.1. Secondary Care
13.4.2. Tertiary Care
14. Americas Autoimmune Disease Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Autoimmune Disease Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Autoimmune Disease Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Johnson & Johnson
17.3.3. Roche Holding AG
17.3.4. Novartis AG
17.3.5. Pfizer Inc.
17.3.6. Bristol-Myers Squibb Company
17.3.7. Sanofi S.A.
17.3.8. Eli Lilly and Company
17.3.9. Amgen Inc.
17.3.10. Merck & Co., Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. AUTOIMMUNE DISEASE DRUGS MARKET MULTI-CURRENCY
FIGURE 2. AUTOIMMUNE DISEASE DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. AUTOIMMUNE DISEASE DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AUTOIMMUNE DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACY WEBSTORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 116. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 118. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 123. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 124. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 125. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 127. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 128. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 130. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 131. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 133. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 134. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 138. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 142. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 143. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 144. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 150. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 153. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 185. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 190. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 231. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 234. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 238. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 239. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 240. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 242. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 243. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 245. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 248. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 249. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 252. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 253. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 258. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 259. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 261. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 262. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 264. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 265. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 267. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 268. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 276. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 277. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 278. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 279. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 280. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 281. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 283. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 284. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 286. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 287. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 290. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 292. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 293. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 295. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 296. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 297. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 298. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 299. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 300. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 302. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 303. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 305. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 306. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 308. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 309. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 310. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 311. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 312. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 314. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 315. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 316. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 317. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 318. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 319. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 320. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2018-2030 (USD MILLION)
TABLE 321. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 322. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323

Companies Mentioned

The companies profiled in this Autoimmune Disease Drugs market report include:
  • AbbVie Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • Eli Lilly and Company
  • Amgen Inc.
  • Merck & Co., Inc.

Methodology

Loading
LOADING...

Table Information